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1778Expanding Indications of
Transcatheter Heart Valve InterventionsABSTRACTTranscatheter aortic valve replacement (TAVR) has been established as a less invasive alternative to open-heart surgery
in inoperable or high-risk patients presenting with symptomatic severe aortic valve stenosis. The feasibility and efﬁcacy
of valve-in-valve implantation in degenerated surgical aortic bioprostheses have also been described and can currently be
considered a valuable treatment option in patients deemed unsuitable for repeat cardiac surgery. However, the clinical
use of TAVR devices is not limited to the treatment of the tricuspid stenotic aortic valve. Several additional indications
including treatment of the bicuspid stenotic aortic valve, aortic regurgitation, and valve-in-valve or valve-in-ring im-
plantation in the mitral or tricuspid position as well as treatment of pure mitral, tricuspid, or pulmonary regurgitation
have been described. The purpose of the present review is to summarize the available evidence concerning the emerging
off-label use of TAVR devices in current clinical practice. Case examples have been selected to highlight the main pro-
cedural steps of each particular intervention. (J Am Coll Cardiol Intv 2015;8:1777–96) © 2015 by the American College of
Cardiology Foundation.D uring the past 10 years, transcatheteraortic valve replacement (TAVR) hasemerged as a valuable minimally invasive
treatment option for patients with symptomatic se-
vere aortic stenosis. TAVR with the SAPIEN valve
(Edwards Lifesciences, Irvine, California) was shown
to be superior to medical treatment in the PARTNER
(Placement of Aortic Transcatheter Valve) B trial,
which found a profound and long-lasting reduction
in mortality through 5 years of follow-up in patients
deemed inoperable (93.6% vs. 71.8%; p < 0.0001)
(1). Comparable results were obtained in extreme
risk patients treated with the Medtronic CoreValve
(MCV) (Medtronic, Minneapolis, Minnesota) trans-
catheter heart valve (2). In patients with severe
aortic stenosis at high surgical risk included in
the PARTNER 1A cohort, TAVR using the balloon-
expandable SAPIEN prosthesis showed similar safety
and efﬁcacy compared with surgical aortic valve
replacement during long-term follow-up (67.8% vs.
62.4% overall mortality; p ¼ 0.76) (3). Along the same
line, TAVR using the self-expanding CoreValve pros-
thesis in patients at increased surgical risk was associ-
ated with lower mortality compared with surgical
aortic valve replacement at 2 years (22.2% vs. 28.6%;
p ¼ 0.04) (4).
On the basis of these data, TAVR is recommended
as the therapy of choice for inoperable patients with
symptomatic severe aortic stenosis with a life ex-
pectancy longer than 1 year (Class IB) and an alter-
native to surgical aortic valve replacement in patients
considered at increased surgical risk (Class IIaB) in
both U.S. and European guidelines.Due to the ease of implantation and favorable
outcomes in observational studies, transcatheter
valve-in-valve (VIV) implantation has been rapidly
embraced for the treatment of degenerated surgical
aortic bioprostheses to avoid redo surgery in the
elderly population. Results from the International
VIV Data Registry reported high procedural success
rates (93.1%) and low periprocedural mortality at 30
days (7.6%) while providing favorable hemodynamic
outcomes (5).
Several other valuable indications have emerged
during the past several years including treatment of
aortic regurgitation (AR), VIV or valve-in-ring (VIR)
implantation of transcatheter heart valves in surgical
prostheses in the mitral or tricuspid position, as well
as treatment of native valve mitral, tricuspid, or
pulmonary regurgitation and stenosis. The purpose of
this review is to summarize the available evidence
concerning the expanding indications of TAVR
devices. Review of the published data and detailed
case descriptions are presented for the following
indications:
1. TAVR for the treatment of pure aortic valve
regurgitation
2. TAVR in native bicuspid aortic valves (BAVs)
3. TAVR for the treatment of transcatheter aortic
valve degeneration
4. Transcatheter valve implantation in the mitral
position
5. Transcatheter valve implantation in the tricuspid
position
6. Treatment of pulmonary valve disease using
transcatheter heart valves
AB BR E V I A T I O N S
AND ACRONYM S
AR = aortic regurgitation
BAV = bicuspid aortic valve
ESV = Edwards SAPIEN valve
LVOT = left ventricular
outﬂow tract
MCV = Medtronic CoreValve
MSCT = multislice computed
tomography
TAVR = transcatheter aortic
valve replacement
TR = tricuspid regurgitation
VIR = valve-in-ring
VIV = valve-in-valve
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1779TAVR FOR THE TREATMENT OF
PURE AORTIC VALVE REGURGITATION
Pure AR is far less frequent than symptomatic aortic
stenosis, affecting w13% of patients with isolated,
native left-sided valvular heart disease (6). Due to
concerns of insufﬁcient anchoring of conventional
transcatheter heart valves within the noncalciﬁed
aortic annulus, surgical valve replacement remains
the treatment of choice in operable patients. How-
ever, the implantation of conventional transcatheter
heart valves not speciﬁcally designed for the treat-
ment of the regurgitant aortic valves has been
described in patients considered at prohibitive risk
for open-heart surgery on a compassionate use basis
(7,8). Due to the self-expanding frame with additional
anchoring by means of abutment also against the
ascending aorta, the self-expanding MCV has been
used in the majority of cases. There is a single report
describing the use of the transapical Medtronic
Engager bioprosthesis (9) and another with the
Edwards SAPIEN XT valve (ESV) in a patient with AR
in the presence of a left ventricular assist device (10).
Adequate deployment of transcatheter heart valves in
an annulus with absent or minimal calciﬁcation re-
mains challenging due to the absence of ﬂuoroscopic
landmarks, the need for oversizing, and the
frequently concomitant dilation of the aortic root
and/or the ascending aorta. Due to these technical
and anatomical issues, valve deployment is less pre-
dictable and may be complicated by supra-annular
(11) (Figure 1) or ventricular dislocation of the pros-
thesis, the latter possibly occurring up to several
hours after implantation (12). To overcome these
technical concerns, some groups advocate the use of
2 pigtail catheters for improved annular delineation
(1 catheter placed in the noncoronary cusp, and the
other placed in the left coronary cusp). Alternatively,
transesophageal echocardiographic visualization may
offer additional guidance, but requires general anes-
thesia. The use of rapid pacing, generally avoided
during the implantation of self-expanding valves, can
be useful in limiting the regurgitant volume as well as
unintended valve motion.
Compared with TAVR for the treatment of native
aortic valve stenosis, transcatheter treatment of pure
AR is associated with a lower device success rate
(74.4%), a higher rate of moderate to severe AR (21%),
and an increased all-cause mortality (21.4%) at
12 months as reported in the largest multicenter study
to date including 43 patients treated with the MCV for
pure AR (13). Recently, another registry reported
comparable results in 26 patients undergoing TAVRwith the MCV (Table 1) (14). Of note, the need
for permanent pacemaker implantation ap-
pears lower in this speciﬁc patient population
compared with conventional TAVR patients
despite the overwhelming use of self-
expanding devices. This might be related at
least in part to the absence of calciﬁc aortic
valve disease involving the surrounding
structures, in particular, the atrioventricular
conduction system.
Several newer generation nondedicated
self-expanding transcatheter prostheses have
been investigated for the treatment of pure
AR. In a small case series, the ACURATE TA
device (Symetis SA, Ecublens, Switzerland)
showed promising results in 8 patients fol-
lowed for 1 year (15). Although there are only limited
clinical data to date, the Lotus Valve System (Boston
Scientiﬁc, Marlborough, Massachusetts) also has the
potential to be successfully used in patients with
pure AR (16) or regurgitant bioprosthetic valves (17)
due to its partially self-expanding, repositionable
design and the adaptive sealing skirt (Figure 2).
Substantial effort has been put into the develop-
ment of dedicated devices enabling capture of aortic
valve leaﬂets thanks to speciﬁc clips to minimize the
risk of valve embolization and paravalvular leaks. The
transapical, self-expanding JenaValve (JenaValve
Technology, Munich, Germany) received CE mark of
approval for the treatment of patients with pure AR in
2013 (18). Mid-term results after 6 months of follow-up
in 31 patients (19) and after 1 year in 10 patients (20)
showed sustained symptomatic improvement and
good hemodynamic performance of the bioprosthesis
with more than mild AR in only 1 patient (successfully
treated with VIV implantation of an ESV after 3 months
of follow-up). A similar system, the J-Valve (JC Medi-
cal, Inc., Redwood City, California), currently un-
dergoes a ﬁrst-in-human investigation in China. The
recently published 90-day follow-up results showed
favorable procedural outcomes with only minor AR
in 90% of the patients. In 1 patient, conversion to sur-
gical valve replacement was required due to device
embolization into the ascending aorta (21).
The Helio transcatheter aortic docking device
(Edwards Lifesciences) is another system designed to
enable annular ﬁxation of a standard balloon-
expandable SAPIEN XT transcatheter heart valve in
patients with a minimally calciﬁed aortic annulus.
The initial version with a combined transapical-
transfemoral approach (22) has recently evolved into
a fully transfemoral system that was successfully
implanted in a patient with severe AR in 2013 (23).
FIGURE 1 Examples of 2 Patients Undergoing Transfemoral TAVR for Treatment of Pure AR Using the MCV
In the ﬁrst patient with severe central aortic regurgitation (A), implantation of a 26-mm Medtronic CoreValve (Medtronic, Minneapolis,
Minnesota) at proper height (B) resulted in almost complete abolition of the regurgitant jet (C); arrow indicates trivial residual AR. In the
second patient (D), slight migration of a 29-mm MCV toward the ascending aorta after release (E) (white arrow indicates the bottom of the
bioprosthesis frame; red line shows the aortic annulus plane) led to mild residual AR (arrow) originating from the noncoronary cusp visualized
by transesophageal echocardiography (F). AR ¼ aortic regurgitation; MCV ¼ Medtronic CoreValve; TAVR ¼ transaortic valve replacement.
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1780TAVR IN BAV
BAV is the most frequent congenital heart defect with
a prevalence of 0.5% to 2.0%, mostly affecting males
(24,25). In as many as 50% of the cases, the valvular
anatomic changes coexist with dilation of the aortic
root and/or the ascending aorta (26). Approximately
20% of the patients 80 years of age and older have
evidence of bicuspid anatomy (either congenital or
due to fusion of severely degenerated leaﬂets) as
observed during surgical aortic valve replacement(27). In clinical practice, a relatively small proportion
of patients (w5%) evaluated for TAVR presents with
bicuspid anatomy. TAVR in BAV remains challenging
due to following anatomic and procedural factors:
1. Difﬁcult valve positioning and anchoring due to
the large anatomy of the ascending aorta and the
elliptical shape of the aortic annulus
2. Incomplete valve frame apposition due to more se-
vere, often eccentric, valve calciﬁcations (28,29)
frequently requiring post-dilation and associated
TABLE 1 Comparative Results of Transcatheter Heart Valves for the Treatment of Pure AR Using Conventional and Dedicated Devices*
First Author, Year (Ref. #)
No. of
Patients Device/Access
Mean STS
Score, %
Mean Log
ES I, %
Device
Success, %†
Second
THV, %
Residual AR
(Grade II
or Higher), % PPM, %
30-Day
Mortality, %
12-Month
Mortality, %
Sarkar et al., 2013 (115) 4 MCV‡/TF NR 50 100 0 0 0 0 NR
Roy et al., 2013 (13) 43 MCV/TF 10 27 74 19 21 16 9 21
Testa et al., 2014 (14) 26 MCV/TF 13 24 77 19 23 5 23 31
Seiffert et al., 2013 (18) 5 JenaValve§/TA 4 20 100 0 0 0 0 NR
Seiffert et al., 2014 (19) 31 JenaValve/TA 5 24 97 3 0 6 13 NR
Schlingloff et al., 2014 (20) 10 JenaValve/TA 7 28 100 0 0 20 30 NR
Wendt et al., 2014 (15) 8 Symetis ACURATEk/TA 7 34 100 0 0 0 0 0
Zhu et al., 2015 (21) 11 J-Valve/TA NR 27 91 0 0 5 0 NR
*Only case series included. †According to Valve Academic Research Consortium. ‡CoreValve, Medtronic, Minneapolis, Minnesota. §JenaValve, JenaValve Technology, Munich, Germany. kSymetis ACURATE,
Ecublens, Switzerland.
AR ¼ aortic regurgitation; ES ¼ EuroSCORE; MCV ¼ Medtronic CoreValve; NR ¼ not reported; PPM ¼ permanent pacemaker; STS ¼ Society of Thoracic Surgeons; TA ¼ transapical; TF ¼ transfemoral;
THV ¼ transcatheter heart valve.
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1781with impaired hemodynamic outcomes (increased
transvalvular gradient or paravalvular leak) (Figure 3).
3. Increased risk of damage to the diseased aortic root
and the ascending aorta during valvuloplasty,
valve implantation, or the post-interventional
course (30).
Numerous case reports have described the feasi-
bility of implanting both self-expanding and
balloon-expandable transcatheter heart valve de-
vices in patients with BAV using transfemoral or
transapical access (31–34). To date, 8 distinct regis-
tries with a total of 381 patients reported on the
outcomes of TAVR in BAV (Table 2). Five registries
compared the performance of TAVR in BAV with
that of TAVR in patients with tricuspid aortic valve
anatomy and observed no signiﬁcant differences inFIGURE 2 Lotus Valve System for the Treatment of AR
In this 56-year-old candidate for left ventricular assist device implantat
27-mm Lotus bioprosthesis (Boston Scientiﬁc, Marlborough, Massachuse
(A) resulted in complete resolution of AR (B). AR ¼ aortic regurgitationterms of device success and cardiovascular mortality
at 1 year (28,35–39). However, in most studies,
bicuspid anatomy was associated with a higher rate
of moderate to severe paravalvular leaks, in partic-
ular if valve sizing was solely on the basis of echo-
cardiography (40). This observation underscores the
beneﬁt of pre-procedural computed tomography of
the aortic root, particularly in patients with uncon-
ventional anatomy. Despite frequent incomplete
valve deployment, only 1 study reported a signiﬁ-
cant increase in the transvalvular aortic valve
gradient compared with TAVR prostheses implanted
in tricuspid anatomy (11.0  2.6 vs. 8.2  2.8;
p ¼ 0.04) (28).
In summary, TAVR may be considered a treat-
ment alternative in selected patients with bicuspidion as a bridge to heart transplantation, transfemoral delivery of a
tts) into a degenerated 27-mm stentless Shelhigh valved conduit
.
FIGURE 3 TAVR for Treatment of a Stenotic BAV
(A–C) In a 74-year-old woman with bicuspid anatomy, multislice computed tomography demonstrated severe asymmetrical annular calciﬁcation
expanding into the sinus of Valsalva between the right and left coronary cusps. (D) Implantation of a 31-mm Medtronic CoreValve led to
incomplete expansion of the bioprosthesis frame, requiring post-dilation with a 26  40-mm balloon. (E) The ﬁnal angiography showed only
mild aortic regurgitation (*). BAV ¼ biscuspid aortic valve; LC ¼ left-coronary; NC ¼ noncoronary; RC ¼ right-coronary.
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1782anatomy. Incomplete valve deployment, particularly
when using self-expandable bioprostheses, may
result in asymmetry of the frame favoring the occur-
rence of an associated paravalvular leak (41) and
accelerating valve deterioration (42). Durability needs
to be addressed by collecting long-term data.
TAVR FOR THE TREATMENT OF
TRANSCATHETER AORTIC VALVE
DEGENERATION
Implantation of a second transcatheter heart valve
either “in series” (i.e., 2 functioning valves) or in a
TAVR device (i.e., only 1 functioning prosthesis) has
been initially described as a bail-out strategy for thetreatment of device embolization (43) as well as for
immediate or delayed treatment of hemodynamically
signiﬁcant paravalvular leak due to either device
malposition (44) or, infrequently, acute leaﬂet dys-
function (45).
More recently, implantation of a second trans-
catheter heart valve for the treatment of bioprosthetic
heart valve degeneration resulting in stenosis or
transvalvular AR several months to years after a
successful TAVR procedure has been proposed
(46–52). For this purpose, self-expandable devices
(CoreValve and Symetis ACURATE TA) have been
mainly used. In 1 case, a second ESV was implanted
via the transapical route 3 years after the ﬁrst inter-
vention (51).
TABLE 2 Summary of the Evidence Supporting Transcatheter Heart Valve Implantation in BAV*
First Author, Year (Ref. #) n Device/Access
Mean STS
Score, %
Mean Log
ES I, %
Device
Success, %†
Residual AR,
Grade II
or Higher PPM
30-Day
Mortality, %
12-Month
Mortality, %
Wijesinghe et al., 2010 (116) 11 ESV‡: 7 TF/4 TA 4 NR 100 27 NR 18 NR
Himbert et al., 2012 (117) 15 MCV§: 14 TF/1 TS 8 17 93 13 40 7 NR
Hayashida et al., 2013 (36) 21 ESV (52%)/MCV (48%)
13 TF/5 TAo /3 TA
NR 20 100 19 14 5 18k
Bauer et al., 2014 (35) 38 ESV (32%)/MCV (68%)
31 TF/1 TAo / 6 TA
NR 18 100 25 17 11 13
Kochman et al., 2014 (37) 28 ESV (18%)/MCV (82%)
22 TF/1 TAo/3 TA /2 TS
NR 19 93 32 29 4 22¶
Costopoulos et al., 2014 (38) 21 ESV (38%)/MCV (62%)
15 TF/1 TA/5 TS
8 24 86 24 14 14# 32#
Mylotte et al., 2014 (40) 139 ESV (34%)/MCV (66%)
109 TF/12 TA/12 TAo/5 TS /1 TC
5 15 90 34 23 5 16**
Yousef et al., 2015 (118) 108 ESV (57%)/MCV (43%)
90 TF/8 TA/5 TAo/5 TS
NR 17 85 10 19 8 17
*Only case series included. †According to Valve Academic Research Consortium. ‡SAPIEN valve, Edwards Lifesciences, Irvine, California. §CoreValve, Medtronic, Minneapolis, Minnesota. kFollow-up data at 12
months available for 11 patients, 2 deaths. ¶Follow-up data at 12 months available for 23 patients, 5 deaths. #Follow-up data at 30 days available for 21 patients, 3 deaths; follow-up data at 12 months
available for 19 patients, 6 deaths. **Follow-up data at 12 months available for 129 patients, 21 deaths.
BAV ¼ biscuspid aortic valve; ESV ¼ Edwards SAPIEN valve; TAo ¼ transaortic; TS ¼ transsubclavian; other abbreviations as in Table 1.
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1783Although several modes of transcatheter heart
valve deterioration have been identiﬁed, including
valve endocarditis, late embolization, and valve
thrombosis, only structural degeneration is amenable
to treatment by percutaneous implantation of a sec-
ond transcatheter heart valve (53) (Figure 4). In
nationwide registries reporting on long-term clinical
outcomes after TAVR (up to 6 years), the incidence of
structural valve failure appears rather low, ranging
between 1.4% and 4.1% (54–56). Furthermore, in both
PARTNER randomized trials, no valve degeneration
has been observed during follow-up as long as 5 years
in >500 TAVR recipients (1,3).
The mechanisms leading to transcatheter bio-
prosthesis deterioration are only incompletely un-
derstood. In surgical valves, calciﬁcation due to
mechanical stress, glutaraldehyde ﬁxation, immuno-
logical reactions, and generalized atherosclerosis
have been identiﬁed as precipitating factors (57).
Although similar mechanisms may act in trans-
catheter heart valve failure, speciﬁc pathophysio-
logical factors including valve stent underexpansion
or interaction with the calciﬁed leaﬂets of the
native aortic valve may also play an important role
(42). Once TAVR-in-transcatheter aortic valve has
been performed, the post-interventional gradient
may represent a source of concern, in particular
in patients with small anatomy and restenotic
valve. Thus, data assessing the durability and
long-term evolution of the transvalvular gradient
after TAVR-in-transcatheter aortic valve need to be
collected.TRANSCATHETER VALVE IMPLANTATION IN
THE MITRAL POSITION
MITRAL VIV IMPLANTATION. Reoperation after mitral
valve intervention is associated with increased peri-
operative mortality and morbidity exceeding 15% in
patients 75 years of age and older (58). Since proof of
principle in 2007 (59) and the ﬁrst description in a
human by Cheung et al. (60) in 2009, transcatheter
VIV implantation in the mitral position has emerged
as an alternative to redo open-heart surgery in
selected high-risk patients. In numerous case reports
and series, favorable clinical outcomes and hemody-
namic results have been reported (Table 3) using
either the transapical or, less frequently, the
transfemoral-transseptal (61) or the transjugular-
transseptal (62) approach. The available experience
suggests an impressive reduction of the mitral
transvalvular gradient or regurgitation severity in
most of the treated patients. However, different types
of procedural complications have been encountered
including prosthesis dysfunction (63), acute (64) or
late valve migration (65), valve thrombosis (66,67) as
well as incomplete apposition resulting in para-
valvular leakage and hemolysis (68). To avoid these
adverse events, several considerations are of partic-
ular importance for the planning of mitral VIV in-
terventions. First, the design of the degenerated
bioprosthesis and its ﬂuoroscopic appearance need to
be well understood. Both play a crucial role when
determining the implantation height of the trans-
catheter heart valve within the surgical bioprosthesis
FIGURE 4 Implantation of a Medtronic CoreValve for Treatment of a Degenerated Edwards SAPIEN Valve
Four years after implantation of a 23-mm Edwards SAPIEN valve, a 85-year-old woman with chronic renal failure presented with recurrent
dyspnea. Transesophageal echocardiography clearly showed thickening and reduced motion of the bioprosthetic leaﬂets (A, arrows) with
recurrent aortic stenosis (B) (mean gradient, 64 mm Hg; aortic valve area, 0.6 cm2). (C, D) Transfemoral implantation of a 26-mm Medtronic
CoreValve successfully treated aortic stenosis (ﬁnal mean gradient, 8 mm Hg; valve area, 1.2 cm2).
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1784(Figure 5). In the absence of radiopaque markers, the
procedure has to be carefully guided by trans-
esophageal echocardiography (69). Implantation of
the transcatheter heart valve too low in the left ven-
tricular cavity may result in left ventricular outﬂow
tract (LVOT) obstruction, whereas deployment of the
bioprosthesis too high may unnecessarily increase the
amount of potentially thrombogenic material in
the left atrium. Second, the true internal diameter of
the surgical valve needs to be precisely assessed by
transesophageal echocardiography and/or multislice
computed tomography (MSCT). Due to the presence
of the leaﬂets mounted inside the valve, the true in-
ternal diameter is typically 1 to 2 mm smaller
compared with the stent diameter reported by the
manufacturer (70). In the presence of calciﬁc material
or pannus, the true internal diameter can even besmaller, allowing implantation of a 29-mm ESV in a
31-mm bioprosthesis or, after careful evaluation, in a
33-mm surgical valve (71). The vast majority of the
mitral VIV interventions have been performed using
the balloon-expandable Edwards SAPIEN XT valves
via the transapical route as they enable reliable
alignment of the transcatheter heart valve in the
surgical bioprosthesis in most of the cases. Because of
the maneuverability of its delivery catheter, the
transfemoral-transseptal route can also be alterna-
tively used with the same device (61). Rapid pacing is
helpful for stabilization of the implantation plane.
In a limited number of patients, the Medtronic
Melody valve has been successfully implanted via the
transfemoral-transseptal route. For this particular
intervention, both the transseptal and percutaneous
transapical approaches are required to create a wire
TABLE 3 Summary of the Published Data Regarding Mitral VIV and VIR Procedures*
First Author, Year (Ref. #) n
Device/
Access
Mean STS
Score, %
Mean Gradient
Post-Procedure, mm Hg, %
Residual MR
(Grade II or Higher), % Stroke, %
Conversion
to SVR, %
Second
Intervention, %†
Valve
Thrombosis, %
30-Day
Mortality, %
12-Month
Mortality, %
Mitral VIV
Cerillo et al., 2011 (119) 3 ESV‡/TA 15 5  1 0 0 33 33 0 33 NR
Seiffert et al., 2012 (121) 6 ESV/TA 19 6  4 0 0 0 33 0 17 NR
Cullen et al., 2013 (72) 9 Melody§
TA þ TF
13 5  2 33 0 0 11k 0 22 NR
Cheung et al., 2013 (71) 23 ESV/TA 12 7  2 0 4 0 4 4 0 9
Schäfer et al., 2014 (75) 8 ESV
3 TA/4 TF/1 TJ
11 5  2¶ 0 13 0 13 0 0 NR
Kliger et al., 2014 (73) 5 Melody
TA þ TF
15 5  2 0 0 20 0 0 0 NR
Wilbring et al., 2014 (76) 9 ESV/TA 12¶ 6  3 0 0 0 0 22# 10 NR
Whisenant et al., 2014 (66) 7 ESV
5 TA/2 TF
NR <5 0 0 14 0 29** NR NR
Bouleti et al., 2015 (61) 6 ESV/TF 18¶ 8  3¶ 0 0 0 17 0 17†† 50††
Mitral VIR
Descoutures et al., 2013 (122) 17 ESV
9 TA/8 TF
13 7  3 12 0 6 0 0 18 29
Schäfer et al., 2014 (75) 4 ESV/TA 9 5  2¶ 0 0 0 0 0 0 NR
Wilbring et al., 2014 (76) 2 ESV
1 TA
12¶ 6  1 0 0 0 0 0 0 NR
Whisenant et al., 2014 (66) 2 ESV/TA NR <5 0 0 0 0 0 NR NR
Bouleti et al., 2015 (61) 11 ESV/TF 18¶ 8  3¶ 9 0 9‡‡ 0 0 0 9
*Only case series included. †Including second valve implantation or surgical access site revision. ‡SAPIEN valve, Edwards Lifesciences, Irvine, California. §Melody valve, Medtronic, Minneapolis, Minnesota. kPercutaneous closure of transseptal puncture site. ¶Mean
gradient includes the VIV and VIR patients published in the same series. #Thrombosis observed after 8 weeks and 3 months in 2 patients on acetylsalicylic acid therapy only. **Thrombosis observed after 11 days and 17 months in 2 patients on acetylsalicylic acid and
clopidogrel therapy only, respectively. ††Including 3 emergent procedures performed in very high risk patients (mean STS ¼ 32%). ‡‡Conversion to open heart surgery at 6 months due to heart failure and pulmonary hypertension.
TJ ¼ transjugular; SVR ¼ surgical valve replacement; MR ¼ mitral regurgitation; VIV ¼ valve in valve; VIR ¼ valve in ring; other abbreviations as in Tables 1 and 2.
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FIGURE 5 Transapical Mitral Valve-in-Valve Implantation
(A) Twelve years after surgical mitral valve replacement using a 33-mm Medtronic Mosaic bioprosthesis, severe mitral valve regurgitation due
to valve degeneration was diagnosed in this 88-year-old man. A 29-mm Edwards SAPIEN XT valve was implanted via the transpical approach
(true inner diameter of the surgical valve, 28 mm). (B) The 3 white arrows show the eyelets on the stent post tips corresponding to the top
of the ventricular part of the surgical valve. For proper implantation, the outﬂow part of the Edwards SAPIEN XT valve needs to be aligned
with the radiopaque markers. Three-dimensional transesophageal echocardiography conﬁrmed the correct position and function of the
transcatheter valve with a limited amount of material in the left atrium (C) and trivial regurgitant jet (D, arrow).
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1786rail between the right femoral vein and the left ven-
tricular apex (72,73). However, some of the limita-
tions of using the Melody valve in this setting are the
relatively small size with a maximal overexpanded
diameter of 24 mm and the length of the covered
valve stent increasing the risk of LVOT obstruction.
In 2015, the ﬁrst successful implantation of a
retrievable valve system, the Direct Flow Medical
valve (25 mm) (Direct Flow Medical Inc., Santa Rosa,
California), has been performed via the transapical
approach for treatment of a regurgitant surgical valve
(Carpentier-Edwards 29 mm) (74). Repositionable
devices may play an important role for transcatheter
mitral valve interventions as they allow for valve
exchange in case of a sizing issue and retrieval in case
of LVOT obstruction.
Overall, hemodynamic assessment after the inter-
vention showed signiﬁcant reduction (but not
normalization) of the transmitral gradient in all caseseries. One study including VIV and VIR procedures
also reported a signiﬁcant increase in cardiac output
(from 3.9  1.0 l/min to 4.6  1.5 l/min) and in valve
area (from 1.6  0.5 cm2 to 2.2  0.5 cm2) as well as a
decrease in left atrial pressure (from 24.3  9.5 mm Hg
to 15.9  4.4 mm Hg) and v-wave (from 44.1  17.1
mm Hg to 22.2  7.6 mm Hg) (75).
Similar to the experience with surgical patients,
antithrombotic therapy plays a crucial role in pre-
venting valve thrombosis, which occurs more
frequently in the mitral position (66). However, there
is no consensus regarding the optimal antithrombotic
regimen. The current practice is to administer oral
anticoagulation along with single antiplatelet therapy
for at least 6 months in all patients who have been
treated with a transcatheter heart valve in the mitral
position. In patients in sinus rhythm, dual antiplate-
let therapy for 6 months can be considered. In 2 in-
dependent studies, the use of single antiplatelet
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1787therapy (either with aspirin or clopidogrel) was found
to be insufﬁcient in preventing late valve thrombosis
(66,76).
MITRAL VIR IMPLANTATION. The mitral VIR proce-
dure was ﬁrst described in ovine models in 2009 us-
ing the 23-mm ESV implanted in a 26-mm Edwards
Physio semirigid complete rings (77). In 2011, a
72-year-old patient underwent implantation of a
balloon-expandable 26-mm ESV in a 28-mm Edwards
Physio ring for the treatment of ischemic mitral
regurgitation 8 years after surgical repair (78). The
ESV was successfully delivered via the transapical
route, achieving good acute hemodynamic results. So
far, most of the published VIR implantations have
been performed using the ESV via the transapical
route. However, some groups have reported the
transfemoral-transseptal approach as a technically
more complex, but less invasive alternative (61). Less
is known about mid- and long-term outcomes of
mitral VIR procedures. Case reports and small series
established the intervention’s safety and feasibility asFIGURE 6 Transapical Mitral Valve-in-Ring Implantation
(A) In an 83-year-old female patient, severe mitral regurgitation recurre
Edwards Physio II ring. After 3-dimensional ring reconstruction by multi
corresponding to a 26-mm Edwards SAPIEN XT valve (B), which was imp
(C). Angiography and echocardiography showed an optimal hemodynam
circularization of the semirigid ring (E).well as the good hemodynamic results (Table 3).
However, due to the D-shape of the annuloplasty
rings, paravalvular leaks were frequently observed
and may be associated with signiﬁcant hemolysis.
From a technical point of view, mitral VIR pro-
cedures are more complex than VIV procedures for
several reasons. As demonstrated by in vitro testing,
the initially elliptical annuloplasty ring has to become
circular during device implantation to accommodate
the transcatheter heart valve and ensure sufﬁcient
sealing. Accordingly, valve deployment can only be
performed in selected deformable complete and rigid
semilunar annuloplasty devices (Online Table 1). In
contrast, complete rigid rings are associated with an
increased risk of stent deformation, impairing leaﬂet
geometry with the possible appearance of trans-
valvular regurgitation. Moreover, the ring circulari-
zation during deployment also has relevant
implications with regard to valve sizing. Rather than
the labeled device diameter as speciﬁed by manu-
facturer, ring perimeter and area, which remain
constant after circularization, are used for valved 3 years after mitral valve reconstruction using a semirigid 30-mm
slice computed tomography, a perimeter of 74.1 mm was measured,
lanted via a transapical access performed in the ﬁfth intercostal space
ic result with only trivial regurgitation (D to F) and complete
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1788selection. Both can be assessed by multislice
computed tomography (MSCT) reconstructions, as
shown in Figure 6B. The ﬁnal diameter (D) of the
annuloplasty ring can also be estimated using the
following formula: D ¼ 2 OðAOpÞ, where A corre-
sponds to the labeled ring area as stated by manu-
facturer. In addition, anatomic aspects regarding the
native anterior mitral leaﬂet deserve consideration.
First, along with its displacement toward the LVOT
during prosthesis deployment, LVOT obstruction
may occur. Second, in the situation of extensive
overlap of the ventricular portion of the prosthetic
valve through the native leaﬂets, the closing forces
exerted over the leaﬂets may be insufﬁcient. This
may cause signiﬁcant transvalvular regurgitation of
the bioprosthesis secondary to leaﬂet dysfunction.
Consequently, procedural success is critically
dependent on both assessment of LVOT dimensions
and careful placement of the transcatheter heart
valve, aiming to position the bioprosthetic stent
frame with equal portions extending into the left
ventricle and the atrium (Figures 6D and 6E).
Three-dimensional reconstructions on the basis of
high-resolution preoperative MSCT allow accurate
prediction of the most direct apical access point
ensuring prosthesis alignment by simulating the
position of the delivery sheath (Figure 6C).
More recently, the use of the Medtronic Melody
valve for VIR interventions was simultaneously re-
ported by 2 different groups (79,80). For this proce-
dure, the same limitations apply as previously
described for the mitral VIV implantation. Due to the
small size of the device, ﬁxation by 2 sutures ﬁxed to
the apex has been proposed to prevent valve embo-
lization (80).
The implantation of a second-generation, reposi-
tionable device, the Direct Flow Medical valve, in a
radiolucent semirigid ring has also been described for
this indication (81). The same advantages apply as for
the VIV intervention in the mitral position along with
the malleability of this speciﬁc device, potentially
allowing better sealing in elliptical rings.
In summary, VIR implantation may be considered
as an alternative to reoperation in selected high-risk
surgical patients after careful evaluation of feasi-
bility depending on ring construction and size.
However, ring deformability cannot be accurately
predicted in every case, so that additional data are
needed to identify factors associated with impaired
circularization (82).
MITRAL VALVE-IN-NATIVE RING IMPLANTATION.
As a variant of mitral VIR implantation, deploy-
ment of transcatheter heart valves into severelycalciﬁed native mitral valve annulus via either the
transfemoral-transseptal (83), the transapical (84), or
the transatrial (85) approach have been reported in
individual patients. The procedure was ﬁrst described
in 2012 by our group (85). For sizing purposes, MSCT
and/or balloon inﬂation have been used. In most of
the patients, the procedural results were satisfactory
from a clinical as well as a hemodynamic point of
view. In the case of on-pump transatrial access, some
groups advocate the placement of additional sutures
to ensure stable anchorage (Figure 7). In one patient
who had this step omitted, valve dislocation and
paravalvular leakage requiring surgical revision
occurred. Finally, the bioprosthesis could be suc-
cessfully secured by suturing to an atrial cuff (76).
This highlights the importance of atrial anchorage for
stabilization of transcatheter heart valves deployed in
the mitral position and certainly has implications for
the design of a dedicated mitral prosthesis.
TRANSCATHETER VALVE IMPLANTATION IN
THE TRICUSPID POSITION
TRICUSPID VIV IMPLANTATION. Tricuspid valve
disease, in particular, tricuspid regurgitation (TR), is
an uncommon condition and has received less
attention in transcatheter heart valve therapy to date.
However, severe TR is associated with a 3-fold
increased all-cause mortality rate and a 4- to 5-fold
increased risk of cardiac events during long-term
follow-up (86). Cardiac surgery for correction of TR
is associated with high perioperative mortality of up
to 10% (87). Importantly, a relevant proportion of
patients requiring tricuspid valve replacement have
already undergone open-heart surgery. In particular,
this is the case for young Ebstein patients requiring
multiple valve replacements because of somatic
growth or bioprosthesis degeneration (88). In these
speciﬁc populations, transcatheter valve implanta-
tion may emerge as a valuable bridging option before
repeat valve surgery (especially for young women of
childbearing age). Transcatheter treatment of degen-
erated tricuspid bioprostheses was ﬁrst explored us-
ing the Melody valve (89). The ﬁrst tricuspid VIV
intervention using a 26-mm ESV in a Medtronic
Mosaic 27-mm bioprosthesis was performed in 2010
using a surgical approach off-pump via a right trans-
atrial access (90). One year later, a fully percutaneous
procedure via the transjugular route was described by
Van Garsse et al. (91) a 23-mm ESV valve. Using the
Edwards RetroFlex delivery system, a 26-mm ESV
could be successfully implanted after pre-stenting in
a 27-mm Edwards Perimount bioprosthesis via the
transfemoral route the same year (92). During the
TABLE 4 Summary of the Published Data Concerning the Tricuspid VIV Procedure*
First Author, Year (Ref. #) n Device/Access
Mean Log
ES I, %
Mean Gradient
Post-Procedure, mm Hg
Residual TR
(Grade II
or Higher), %
Conversion
to SVR, %
Second
Intervention, %†
Valve
Thrombosis
30-Day
Mortality, %
12-Month
Mortality, %
Roberts et al., 2011 (120) 15 Melody‡§
11 TF/4 TJ
NR 3  2 7 7 0 0 7 NR
Cheung et al., 2012 (123) 3 ESVk/transatrial 27 7  3 0 0 0 0 33 NR
Cullen et al., 2013 (72) 10 Melody
TF or TJ
NR 2  1 10 10 10 10¶ 0 NR
Godart et al., 2014 (95) 10 ESV/
Melody
NR 4  1 0 0 20 0 0 NR
Tzifa et al., 2014 (124) 5 ESV/
Melody
4 TJ/1 TF
NR 3  2 0 0 0 0 0 0
Eicken et al., 2015 (93) 16 ESV/
Melody
TF
NR 3  2 0 6 0 0 0 0#
*Only case series included. †Including second valve implantation or surgical access site revision. ‡Melody valve, Medtronic, Minneapolis, Minnesota. §Implantation into a dysfunctional right atrial–right
ventricular conduit in 5 patients. kSAPIEN valve, Edwards Lifesciences, Irvine, California. ¶Valve thrombosis due to heparin-induced thrombocytopenia. #Follow-up data at 12 months available for 9 patients,
0 deaths.
Mean gradient post ¼ mean post-procedural gradient or mean gradient after the procedure; TR ¼ tricuspid regurgitation; other abbreviations as in Tables 1 to 3.
FIGURE 7 Transatrial On-Pump Mitral Valve-in-Native Ring Implantation
In selected patients presenting with severely calciﬁed mitral valve annulus not amenable to decalciﬁcation (A, B arrows delineate the calciﬁed
native mitral valve annulus), on pump transatrial implantation of a transcatheter heart valve emerged as a possible alternative. After pre-
dilation, a 26-mm Edwards SAPIEN XT valve was implanted via a transatrial approach using the Edwards Ascendra delivery catheter (C, D) in
this 61-year-old male patient with severe mitral stenosis (mean gradient, 17 mm Hg; mitral valve area, 0.9 cm2). To avoid migration, the valve
was sutured to the mitral annulus (E). Echocardiographic assessment showed mild residual mitral regurgitation. The post-operative course was
uneventful.
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1790following years, several case reports and 4 case series
conﬁrmed the safety and feasibility of this interven-
tion using either the Melody valve or the ESV
(Table 4). Only 1 case of valve thrombosis involving a
Melody valve has been reported so far and was shown
to be related to heparin-induced thrombocytopenia
(72).
Several technical issues need to be considered
when planning a tricuspid VIV implantation. First,
the most appropriate access route needs to be
determined. The less invasive transjugular and
transfemoral approaches may be preferred to avoid
thoracotomy in patients presenting with relevant
comorbidities, in particular, chronic pulmonary
disease. Although the transjugular access offers the
most direct route to the tricuspid plane, catheter
maneuverability enables transfemoral implantation
in most patients. In either case, an extra stiff wire is
positioned in the pulmonary artery, ensuring sufﬁ-
cient stabilization and traveling of the transcatheter
heart valve through the right atrium into the
ventricle (Figure 8C). Second, the valve type and
size must be appropriately selected. For this pur-
pose, conventional valve assessment using multi-
modal imaging (Figures 8A and 8B) as well as
balloon sizing have been used (93). Due to greater
availability and larger sizes, the ESV is the preferred
system for this indication. However, the shorter
frame compared with the Melody valve may impair
coaxial alignment and render the bioprosthesis
more prone to dislocation. To overcome this limi-
tation, pre-stenting of the surgical valve (e.g.,
Cheatham-Platinum stent) has been proposed in
particular in bioprostheses exceeding a labeled
diameter of 30 mm. Pre-stenting was also recently
described as a lead protection strategy in a patient
with an implantable cardioverter deﬁbrillator, which
usually represents a contraindication to a VIV
intervention in the tricuspid position. The deﬁbril-
lator function could be preserved without changes
in lead impedance after 1 year during the follow-up
period (94). Although not mandatory, rapid pacing
during the procedure can be obtained by placement
of a transarterial temporary pacing lead in either the
left ventricle or the sinus coronarius. Alternatively,
right ventricular guidewire pacing can be attempted.
Pooled hemodynamic data from case reports
demonstrated acceptable valve performance with a
mean transvalvular gradient of 3.8  2.0 mm Hg
and moderate regurgitation in only 1 patient (of 71
cases reported) (95). Cardiac magnetic resonance
imaging performed in 5 patients showed an incon-
sistent hemodynamic response. The right ventricu-
lar end-diastolic volume decreased in 2 patients,increased in 1 patient, and remained unchanged in
2 patients (93).
Online Table 2 summarizes the surgical bio-
prostheses amenable to VIV intervention according
to the published data. As also observed in a small
proportion of patients with a surgical valve, early
bioprosthesis degeneration was described in 3
patients treated by implantation of a Melody valve in
the tricuspid position and in 1 patient with a 23-mm
ESV (96). The cause of early degeneration may be
associated with the particular hemodynamic envi-
ronment, but the exact reason is still unknown.
TRICUSPID VIR IMPLANTATION. In contrast to mitral
VIR, the experience with tricuspid VIR implantation
is limited. To date, 4 case reports (97–100) and 1 case
series including 3 patients (101) have been published.
In 1 patient, the intervention included the simulta-
neous VIR implantation of 2 ESVs in mitral and
tricuspid positions successfully performed via a
transatrial off-pump approach (97). Another report
described the treatment of a severe tricuspid stenosis
after implantation of a mitral valve homograft with a
34-mm Edwards Physio ring. After pre-dilation and
pre-stenting with an Intrastent LD Max (Covidien,
Mansﬁeld, Massachusetts), a 26-mm ESV could be
implanted with a good ﬁnal hemodynamic result
(3-mm Hg mean gradient and trivial regurgitation)
(98). In 1 patient, the procedure was combined with
the immediate implantation of an Amplatzer vascular
plug for correction of residual paravalvular leak be-
tween the Melody valve and the ring (100). Finally,
the recent case series by Bouleti et al. (61) reported
1-year outcomes in 3 patients who had a 26-mm
ESV successfully implanted in 2 30-mm and one
32-mm Carpentier-Edwards Classic rings, respec-
tively. At 1 year, all patients were alive with a mean
transvalvular gradient <5 mm Hg. However, 1 patient
treated for severe TR still had moderate to severe TR
due to incomplete apposition of the newly implanted
device.
In contrast to the most frequently used mitral
annuloplasty rings, the devices designed for tricuspid
reconstruction are rigid, oval, and incomplete to
prevent damage to the cardiac conduction system.
This particularity complicates the selection of a suit-
able transcatheter heart valve. For appropriate deci-
sion making, balloon sizing should be performed
before the ﬁnal selection of the bioprosthesis. After
implantation, only limited circularization and in-
complete sealing of the ESV into the annuloplasty
ring with subsequent relevant paravalvular regurgi-
tation has been observed in some cases (101) and may
need to be addressed (100).
FIGURE 8 Transfemoral Tricuspid Valve-in-Valve Implantation
A 41-year-old woman known for Ebstein anomaly presented with symptomatic tricuspid stenosis 6 years after surgical tricuspid valve
replacement (33-mm Edwards Perimount Magna). Members of the Heart Team decided that transcatheter valve implantation should be
performed as a bridge to repeat surgery in this woman of childbearing age. Transesophageal echocardiography showed the stenosis to be
related to immobilization and thickening a valve leaﬂet (A, white arrow). The baseline mean gradient was 10 mm Hg. Sizing of the surgical
valve using multislice computed tomography (B) showed that the valve perimeter and area was amenable to implantation of a 29-mm Edwards
SAPIEN valve (external diameter, 32.8 mm; internal perimeter, 88 mm; internal area, 616.3 mm2; perimeter-derived area, 28 mm). Trans-
catheter valve replacement was successfully performed via the transfemoral approach after placement of a stiff wire in the right pulmonary
artery (C). (D, E) Final assessment shows no valve regurgitation and a mean gradient of 4 mm Hg. Spiroergometry 3 months after the
intervention documented notable improvement of exercise capacity.
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1791According to this early experience in a limited
number of patients, tricuspid VIR implantation using
the contemporary devices seems more prone to the
appearance of associated paravalvular leakage and
requires careful evaluation. In the future, the use of
repositionable or dedicated devices may increase
safety and predictability of the intervention.
CAVAL VALVE IMPLANTATION FOR THE
TREATMENT OF TRICUSPID REGURGITATION
Alternative approaches aiming to reduce regurgita-
tion into the inferior vena cava and possibly the su-
perior vena cava have been recently proposed
(102,103). In 2011, implantation of a dedicated valved
stent in the inferior vena cava resulted in reduction of
symptoms. In another ﬁrst-in-human study, deploy-
ment of a 29-mm ESV in the inferior vena cava in 2
patients and in both the superior vena cava and theinferior vena cava in 1 patient was carried out from the
right femoral vein. Due to caval enlargement, pre-
stenting with 2 self-expanding stents was required
to downsize the inferior vena cava to a diameter
allowing secure implantation of a 29-mm ESV.
The intervention, eventually leading to ventriculari-
zation of the right atrium, was followed by clinical
improvement in all patients. However, several limi-
tations prevent the widespread availability of this
technique. First, caval diameter may exceed 30 mm in
an large proportion of patients presenting with rele-
vant TR. Second, it does not resolve impaired cardiac
output associated with TR and does not prevent
further deterioration of right ventricular function.
Additionally, the high costs of the treatment need to
be balanced against the net clinical beneﬁt. Consid-
ering these points, the technique should be offered to
patients presenting with intractable heart failure on a
compassionate use basis.
TABLE 5
First Auth
Boone et
Kenny et
Faza et al
Haas et al
Odemis et
Demkow e
*SAPIEN va
PR ¼ pulm
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1792TRANSCATHETER VALVE IMPLANTATION IN
THE PULMONARY POSITION
Percutaneous pulmonary valve implantation was ﬁrst
performed using the Medtronic Melody valve. The
intervention was described in 2000 in a 12-year-old
boy with degeneration of a prosthetic conduit (104).
In the meantime, good short- and long-term hemo-
dynamic and functional results have been observed
(105,106). In addition, favorable outcomes after
Melody-in-Melody implantation for the treatment of
device failure has also been demonstrated (107).
However, as is the case for the indications previously
described, the use of the Melody valve is limited by
its small size and the risk of stent fracture. For these
reasons, transcatheter heart valves initially designed
to be delivered in the aortic position have been
explored on a compassionate use basis. In 2006,
a 23-mm Edwards-Cribier valve was successfully
implanted in a previously stented 24-mm homograft
in a 16-year old girl having undergone a Ross opera-
tion at 14 years of age (108). Subsequently, the valve
was successfully evaluated for treatment of pulmo-
nary stenosis or regurgitation in patients with or
without degenerated valved conduit (Table 5) and
received CE approval for percutaneous pulmonary
valve implantation in 2010. Only 1 study compared
the Melody valve with the ESV and found, except for
a slightly increased transvalvular gradient in the ESV
group, similar short- and midterm outcomes (109). In
single cases, VIV delivery of the ESV in the pulmonary
position, either in a previously implanted Melody
valve or in a surgical bioprosthesis, has been shown
to be feasible (106,110). As an alternative access, a
surgical subxiphoid approach through the right
ventricle has been proposed (111).
As encountered with the Melody valve, coronary
compression may also occur using the ESV (112).
Abnormal coronary anatomy emerged as the principal
risk factor (113). Preinterventional MSCT used forShort-Term Results After Implantation of an ESV* in the Pulmonary Po
or, Year (Ref. #) n
Device
Success, %
Mean Gradient
Post-Procedure, mm Hg
Residu
(Grade I or
al., 2010 (125) 7 100 15  7 0
al., 2011 (126) 36 86 12  8 6
., 2013 (109) 20 100 11  8 0
., 2013 (127) 22 95 7  3 0
al., 2013 (128) 7 100 6  4 0
t al., 2014 (129) 10 90 5  4 0
lve, Edwards Lifesciences, Irvine, California. †Only case series included.
onary regurgitation; other abbreviations as in Table 2.careful analysis of the coronary anatomy combined
with selective coronary angiography during simulta-
neous balloon inﬂation in the right ventricular
outﬂow tract prevents this complication in the ma-
jority of the patients. According to a recent systematic
review, valve endocarditis after percutaneous pul-
monary valve implantation seems to be more fre-
quent than in the aortic position and may exceed the
corresponding risk for surgical patients (2.2% vs.
1.3%). These ﬁndings warrant further investigations
to identify situations at risk and predictors of
disease (114).
CONCLUSIONS
At this early stage, the expanded use of TAVR devices
in alternative valvular positions or for other in-
dications than initially intended appears feasible and
safe. In the light of the published experience, the
following points deserve consideration:
1. Treatment of pure AR with conventional devices is
associated with rather low device success rate
(w75%) and the need of a second valve in 20% of
the patients. These results support the ongoing
development of dedicated systems.
2. TAVR in bicuspid anatomy is feasible, but associ-
ated with a higher incidence of paravalvular leaks.
3. TAVR-TAV emerges as a valuable option for treat-
ment of valvular degeneration.
4. Transcatheter mitral VIV or VIR interventions are
characterized by overall good efﬁcacy in reducing
mitral regurgitation or treating mitral stenosis and
low rates of complications. However, careful
evaluation of the prosthesis/ring type and size
using multimodality imaging is necessary. Appro-
priate antithrombotic therapy is crucial to avoid
valve thrombosis.
5. Although rarely performed, tricuspid VIV pro-
cedures may emerge as an attractive treatment
option. In contrast, tricuspid VIR implantationsition†
al PR
Higher), %
Valve/Stent
Embolization, %
Conversion
to SVR, %
Second
Valve, %
30-Day
Mortality, %
0 0 0 0
11 9 3 0
5 5 5 0
5 0 5 0
0 0 0 0
10 10 0 0
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1793performed with the currently available devices are
limited by the design of tricupid rings.
6. Caval valve(s) implantation has been shown to be
feasible and will compete with dedicated devices
designed for the treatment of the native tricuspid
valve.
7. Due to broader experience, the implantation of the
Melody valve is still preferred for percutaneous
pulmonary valve implantation. For particular in-
dications, especially patients with large anatomy,
the ESV represents an useful alternative.
Importantly, the innovative approaches summa-
rized in this review mainly concern patients having
previously undergone open-heart surgery. As such,they may emerge as valuable treatment options for
patients otherwise treated medically or exposed to
the increased risk of repeat valve surgery. The
growing experience with the off-label use of TAVR
devices may be of crucial importance for the
future development of transcatheter techniques spe-
ciﬁcally designed to treat tricuspid and mitral valve
disease.
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